

```

=> File .Biotech
=> s (hydroxypropyl alpha cyclodextrin or alpha cyclodextrin or HP alpha CD?)
5 FILES SEARCHED...
L1      8389 (HYDROXYPROPYL ALPHA CYCLODEXTRIN OR ALPHA CYCLODEXTRIN OR HP
        ALPHA CD?)

=> s l1 and (lyophil? or freeze dried or dry?)
L2      1276 L1 AND (LYOPHIL? OR FREEZE DRIED OR DRY?)

=> s l2 and (stabil? or stabl?)
4 FILES SEARCHED...
L3      891 L2 AND (STABIL? OR STABL?)

=> s l3 and (fibrinogen or factor II or VII or Ix or X)
L4      484 L3 AND (FIBRINOGEN OR FACTOR II OR VII OR IX OR X)

=> s l4 and (albumin or fibronectin or protein C or S or gamma globulin)
L5      457 L4 AND (ALBUMIN OR FIBRONECTIN OR PROTEIN C OR S OR GAMMA GLOBU
        LIN)

=> s l5 and (virus inactivat?)
L6      3 L5 AND (VIRUS INACTIVAT?)

```

```

=> d l6 1-3 bib ab

```

```

L6      ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2003 ACS

```

```

AN      1997:717823  CAPLUS

```

```

DN      127:351177

```

```

TI      A process for viral inactivation of lyophilized blood proteins

```

```

IN      Bhattacharya, Prabir; Motokubota, Toshiharu

```

```

PA      Alpha Therapeutic Corp., USA

```

```

SO      PCT Int. Appl., 19 pp.

```

```

        CODEN: PIXXD2

```

```

DT      Patent

```

```

LA      English

```

```

FAN.CNT 1

```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9739761	A1	19971030	WO 1997-US6585	19970417
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2252374	AA	19971030	CA 1997-2252374	19970417
	EP 954326	A1	19991110	EP 1997-921280	19970417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000509374	T2	20000725	JP 1997-538228	19970417
	US 2001047085	A1	20011129	US 2001-894346	20010628
PRAI	US 1996-634921	A	19960419		
	WO 1997-US6585	W	19970417		
	US 1998-166875	A3	19981006		

```

AB      The invention relates to a process for the viral inactivation of
lyophilized blood proteins, particularly Factor VIII, by heat
comprising forming a stable complex between the blood protein
and a cyclodextrin in an aq. soln. The soln. is then lyophilized
and the blood protein/cyclodextrin complex is recovered. The
lyophilized blood protein/cyclodextrin is then heated, e.g., to
80.degree. for 72 h, to inactivate any virus present. The material may
then be reconstituted prior to administration to a patient.

```

```

L6      ANSWER 2 OF 3  USPATFULL

```

```

AN      2001:218593  USPATFULL

```

```

TI      Process for viral inactivation of lyophilized blood proteins

```

```

IN      Bhattacharya, Prabir, Walnut, CA, United States

```

```

        Motokubota, Toshiharu, Arcadia, CA, United States

```

Fedalizo, Norman M., Rowland Heights, CA, United States  
PA Alpha Therapeutic Group (U.S. corporation)  
PI US 2001047085 A1 20011129  
AI US 2001-894346 A1 20010628 (9)  
RLI Division of Ser. No. US 1998-166875, filed on 6 Oct 1998, PENDING  
Continuation of Ser. No. US 1996-634921, filed on 19 Apr 1996, ABANDONED  
DT Utility  
FS APPLICATION  
LREP CHRISTIE, PARKER & HALE, LLP, 350 WEST COLORADO BOULEVARD, SUITE 500,  
PASADENA, CA, 91105  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 335

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the viral inactivation of **lyophilized** blood proteins, particularly Factor VIII, by heat comprising forming a **stable** complex between the blood protein and a cyclodextrin in an aqueous solution. The solution is then **lyophilized** and the blood protein/cyclodextrin complex is recovered. The **lyophilized** blood protein/cyclodextrin is then heated, e.g., to 80.degree. C. for 72 hours, to inactivate any virus present. The material may then be reconstituted prior to administration to a patient.

L6 ANSWER 3 OF 3 USPATFULL

AN 97:73722 USPATFULL

TI Anion exchange process for the purification of Factor VIII

IN Bhattacharya, Prabir, Walnut, CA, United States

Motokubota, Toshiharu, Arcadia, CA, United States

Fedalizo, Norman M., Rowland Heights, CA, United States

PA Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)

PI US 5659017 19970819

AI US 1995-554724 19951107 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Schain, Howard E.

LREP Christie, Parker & Hale, LLP

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 8 Drawing Page(s)

LN.CNT 866

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method for purifying Factor VIII complex from an impure protein fraction, usually cryoprecipitate, is disclosed. The cryoprecipitate is dissolved in a heparin solution. Then Factor VIII complex is initially purified by polyethylene glycol precipitation. The Factor VIII containing supernatant collected after the precipitation is loaded into an anion exchange column that has a quaternary amino ethyl group. The Factor VIII complex is then eluted from the column with a buffer comprising from about 0.14M to about 0.20M CaCl<sub>2</sub>. The final step in the purification is to precipitate the Factor VIII complex in the presence of glycine and sodium chloride. The precipitated Factor VIII complex is then reconstituted and **stabilized**. The reconstituted Factor VIII complex can then be **lyophilized** and **dry** heated to obtain a final Factor VIII product.

=> d his

(FILE 'HOME' ENTERED AT 17:52:30 ON 09 FEB 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, BIOTECHDS, EMBASE, USPATFULL, WPIDS'  
ENTERED AT 17:52:50 ON 09 FEB 2003

L1 8389 S (HYDROXYPROPYL ALPHA CYCLODEXTRIN OR ALPHA CYCLODEXTRIN OR HP

L2 1276 S L1 AND (LYOPHIL? OR FREEZE DRIED OR DRY?)  
 L3 891 S L2 AND (STABIL? OR STABL?)  
 L4 484 S L3 AND (FIBRINOGEN OR FACTOR II OR VII OR IX OR X)  
 L5 457 S L4 AND (ALBUMIN OR FIBRONECTIN OR PROTEIN C OR S OR GAMMA GL  
 L6 3 S L5 AND (VIRUS INACTIVAT?)

=> s 16 and (hydroxypropyl alpha cyclodextrin)  
 L7 0 L6 AND (HYDROXYPROPYL ALPHA CYCLODEXTRIN)

=> s (hydroxypropyl alpha cyclodextrin)  
 L8 0 (HYDROXYPROPYL ALPHA CYCLODEXTRIN)

=> s (hydroxypropyl cyclodextrin)  
 L9 460 (HYDROXYPROPYL CYCLODEXTRIN)

=> s 15 and 16  
 L10 3 L5 AND L6

=> d 110 1-3 bib ab

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

AN 1997:717823 CAPLUS

DN 127:351177

TI A process for viral inactivation of **lyophilized** blood proteins

IN Bhattacharya, Prabir; Motokubota, Toshiharu

PA Alpha Therapeutic Corp., USA

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9739761	A1	19971030	WO 1997-US6585	19970417
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2252374	AA	19971030	CA 1997-2252374	19970417
	EP 954326	A1	19991110	EP 1997-921280	19970417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000509374	T2	20000725	JP 1997-538228	19970417
	US 2001047085	A1	20011129	US 2001-894346	20010628
PRAI	US 1996-634921	A	19960419		
	WO 1997-US6585	W	19970417		
	US 1998-166875	A3	19981006		

AB The invention relates to a process for the viral inactivation of **lyophilized** blood proteins, particularly Factor VIII, by heat comprising forming a **stable** complex between the blood protein and a cyclodextrin in an aq. soln. The soln. is then **lyophilized** and the blood protein/cyclodextrin complex is recovered. The **lyophilized** blood protein/cyclodextrin is then heated, e.g., to 80.degree. for 72 h, to inactivate any virus present. The material may then be reconstituted prior to administration to a patient.

L10 ANSWER 2 OF 3 USPATFULL

AN 2001:218593 USPATFULL

TI Process for viral inactivation of **lyophilized** blood proteins

IN Bhattacharya, Prabir, Walnut, CA, United States

Motokubota, Toshiharu, Arcadia, CA, United States

Fedalizo, Norman M., Rowland Heights, CA, United States

PA Alpha Therapeutic Group (U.S. corporation)

PI US 2001047085 A1 20011129

AI US 2001-894346 A1 20010628 (9)

RLI Division of Ser. No. US 1998-166875, filed on 6 Oct 1998, PENDING

Continuation of Ser. No. US 1996-634921, filed on 19 Apr 1996, ABANDONED

DT Utility  
FS APPLICATION  
LREP CHRISTIE, PARKER & HALE, LLP, 350 WEST COLORADO BOULEVARD, SUITE 500,  
PASADENA, CA, 91105  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 335  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A process for the viral inactivation of **lyophilized** blood proteins, particularly Factor VIII, by heat comprising forming a **stable** complex between the blood protein and a cyclodextrin in an aqueous solution. The solution is then **lyophilized** and the blood protein/cyclodextrin complex is recovered. The **lyophilized** blood protein/cyclodextrin is then heated, e.g., to 80.degree. C. for 72 hours, to inactivate any virus present. The material may then be reconstituted prior to administration to a patient.

L10 ANSWER 3 OF 3 USPATFULL  
AN 97:73722 USPATFULL  
TI Anion exchange process for the purification of Factor VIII  
IN Bhattacharya, Prabir, Walnut, CA, United States  
Motokubota, Toshiharu, Arcadia, CA, United States  
Fedalizo, Norman M., Rowland Heights, CA, United States  
PA Alpha Therapeutic Corporation, Los Angeles, CA, United States (U.S. corporation)  
PI US 5659017 19970819  
AI US 1995-554724 19951107 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Schain, Howard E.  
LREP Christie, Parker & Hale, LLP  
CLMN Number of Claims: 23  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 8 Drawing Page(s)  
LN.CNT 866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method for purifying Factor VIII complex from an impure protein fraction, usually cryoprecipitate, is disclosed. The cryoprecipitate is dissolved in a heparin solution. Then Factor VIII complex is initially purified by polyethylene glycol precipitation. The Factor VIII containing supernatant collected after the precipitation is loaded into an anion exchange column that has a quaternary amino ethyl group. The Factor VIII complex is then eluted from the column with a buffer comprising from about 0.14M to about 0.20M CaCl<sub>2</sub>. The final step in the purification is to precipitate the Factor VIII complex in the presence of glycine and sodium chloride. The precipitated Factor VIII complex is then reconstituted and **stabilized**. The reconstituted Factor VIII complex can then be **lyophilized** and **dry** heated to obtain a final Factor VIII product.

=> s 16 and (hydroxypropyl cyclodextrin complex)  
L11 0 L6 AND (HYDROXYPROPYL CYCLODEXTRIN COMPLEX)

=> s 16 and (lyophilized blood protein)  
L12 2 L6 AND (LYOPHILIZED BLOOD PROTEIN)

=> d 112 1-2 bib ab

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS  
AN 1997:717823 CAPLUS  
DN 127:351177  
TI A process for viral inactivation of **lyophilized** blood proteins  
IN Bhattacharya, Prabir; Motokubota, Toshiharu



PA Alpha Therapeutic Corp., USA  
SO PCT Int. Appl., 19 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9739761	A1	19971030	WO 1997-US6585	19970417
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2252374	AA	19971030	CA 1997-2252374	19970417
	EP 954326	A1	19991110	EP 1997-921280	19970417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000509374	T2	20000725	JP 1997-538228	19970417
	US 2001047085	A1	20011129	US 2001-894346	20010628
PRAI	US 1996-634921	A	19960419		
	WO 1997-US6585	W	19970417		
	US 1998-166875	A3	19981006		

AB The invention relates to a process for the viral inactivation of **lyophilized** blood proteins, particularly Factor VIII, by heat comprising forming a **stable** complex between the blood protein and a cyclodextrin in an aq. soln. The soln. is then **lyophilized** and the blood protein/cyclodextrin complex is recovered. The **lyophilized blood protein/cyclodextrin** is then heated, e.g., to 80.degree. for 72 h, to inactivate any virus present. The material may then be reconstituted prior to administration to a patient.

L12 ANSWER 2 OF 2 USPATFULL  
AN 2001:218593 USPATFULL  
TI Process for viral inactivation of **lyophilized** blood proteins  
IN Bhattacharya, Prabir, Walnut, CA, United States  
Motokubota, Toshiharu, Arcadia, CA, United States  
Fedalizo, Norman M., Rowland Heights, CA, United States  
PA Alpha Therapeutic Group (U.S. corporation)  
PI US 2001047085 A1 20011129  
AI US 2001-894346 A1 20010628 (9)  
RLI Division of Ser. No. US 1998-166875, filed on 6 Oct 1998, PENDING  
Continuation of Ser. No. US 1996-634921, filed on 19 Apr 1996, ABANDONED  
DT Utility  
FS APPLICATION  
LREP CHRISTIE, PARKER & HALE, LLP, 350 WEST COLORADO BOULEVARD, SUITE 500,  
PASADENA, CA, 91105  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 335

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the viral inactivation of **lyophilized** blood proteins, particularly Factor VIII, by heat comprising forming a **stable** complex between the blood protein and a cyclodextrin in an aqueous solution. The solution is then **lyophilized** and the blood protein/cyclodextrin complex is recovered. The **lyophilized blood protein/cyclodextrin** is then heated, e.g., to 80.degree. C. for 72 hours, to inactivate any virus present. The material may then be reconstituted prior to administration to a patient.

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 18:08:31 ON 09 FEB 2003